Vagus-brain communication in atherosclerosis-related inflammation: A neuroimmunomodulation perspective of CAD

Atherosclerosis

Volumn 195, Issue 2, 2007, Pages

  Gidron, Yori ^a   Kupper, Nina ^a   Kwaijtaal, Martijn ^a   Winter, Jobst ^b   Denollet, Johan ^a  

^a TILBURG UNIVERSITY   (Netherlands)

^b CPRLab   (Netherlands)

Author keywords

Atherosclerosis; Autonomic nervous system; Coronary artery disease; Inflammation; Vagus nerve

Indexed keywords

ATROPINE; GLYCERYL TRINITRATE; INTERLEUKIN 1; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; MIGRATION INHIBITION FACTOR; PLACEBO; SCOPOLAMINE; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD BRAIN BARRIER; BRAIN REGION; CARDIOLOGY; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DRUG ACTIVATION; DRUG MECHANISM; ELECTROCARDIOGRAM; HEART FUNCTION; HEART INFARCTION; HEART RATE VARIABILITY; HUMAN; IMMUNOMODULATION; INFLAMMATION; LOW DRUG DOSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SMOOTH MUSCLE FIBER; VAGUS NERVE STIMULATION;

ANIMALS; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DOGS; HUMANS; INFLAMMATION; NEUROIMMUNOMODULATION; PARAGANGLIA, NONCHROMAFFIN; RATS; RELAXATION TECHNIQUES; VAGUS NERVE;

EID: 36049003122     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.10.009     Document Type: Review

References (88)

1. Libby P., and Theroux P. Pathophysiology of coronary artery disease. Circulation 111 (2005) 3481-3488
2. Dantzer R. Innate immunity at the forefront of psychoneuroimmunology. Brain Behav Immun 18 (2004) 1-6
3. Tracey K.J. The inflammatory reflex. Nature 420 (2002) 853-859
4. Gidron Y., Perry H., and Glennie M. Does the vagus nerve inform the brain about preclinical tumours and modulate them?. Lancet Oncol 6 (2005) 245-248
5. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 138 (1999) S419-S420
6. Ramkumar N., Cheung A.K., Pappas L.M., Roberts W.L., and Beddhu S. Association of obesity with inflammation in chronic kidney disease: a cross-sectional study. J Ren Nutr 14 (2004) 201-207
7. Helmersson J., Larsson A., Vessby B., and Basu S. Active smoking and a history of smoking are associated with enhanced prostaglandin F2[alpha], interleukin-6 and F2-isoprostane formation in elderly men. Atherosclerosis 181 (2005) 201
8. Dalekos G.N., Elisaf M., Bairaktari E., Tsolas O., and Siamopoulos K.C. Increased serum levels of interleukin-1beta in the systemic circulation of patients with essential hypertension: additional risk factor for atherogenesis in hypertensive patients?. J Lab Clin Med 129 (1997) 300-308
9. Libby P., and Lee R.T. Matrix matters. Circulation 102 (2000) 1874-1876
10. Shah P.K., Falk E., Badimon J.J., et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 92 (1995) 1565-1569
11. Chen F., Eriksson P., Hansson G.K., et al. Expression of matrix metalloproteinase 9 and its regulators in the unstable coronary atherosclerotic plaque. Int J Mol Med 15 (2005) 57-65
12. Schober A., Bernhagen J., Thiele M., et al. Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. Circulation 109 (2004) 380-385
13. Schroeder A.P., and Falk E. Pathophysiology and inflammatory aspects of plaque rupture. Cardiol Clin 14 (1996) 211-220
14. Lutgens E., van Suylen R.J., Faber B.C., et al. Atherosclerotic plaque rupture: local or systemic process?. Arterioscler Thromb Vasc Biol 23 (2003) 2123-2130
15. Takahashi H., Nishimura M., Sakamoto M., Ikegaki I., Nakanishi T., and Yoshimura M. Effects of interleukin-1 beta on blood pressure, sympathetic nerve activity, and pituitary endocrine functions in anesthetized rats. Am J Hypertens 5 (1992) 224-229
16. Kalsch T., Elmas E., Nguyen X.D., et al. Enhanced expression of platelet CD40-ligand by in vitro lipopolysaccharide-challenge in patients with ventricular fibrillation complicating acute myocardial infarction. Int J Cardiol 107 (2006) 350
17. Oleksowicz L., Mrowiec Z., Schwartz E., Khorshidi M., Dutcher J.P., and Puszkin E. Characterization of tumor-induced platelet aggregation: the role of immunorelated GPIb and GPIIb/IIIa expression by MCF-7 breast cancer cells. Thromb Res 79 (1995) 261-274
18. Neumann F.-J., Marx N., Gawaz M., et al. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. Circulation 95 (1997) 2387-2394
19. Zamotrinsky A., Afanasiev S., Karpov R.S., and Cherniavsky A. Effects of electrostimulation of the vagus afferent endings in patients with coronary artery disease. Coron Artery Dis 8 (1997) 551-557
20. Esler M., and Kaye D. Increased sympathetic nervous system activity and its therapeutic reduction in arterial hypertension, portal hypertension and heart failure. J Auton Nerv Syst 72 (1998) 210-219
21. Julius S., and Nesbitt S. Clinical consequences of the autonomic imbalance in hypertension and congestive heart failure. Scand Cardiovasc J Suppl 47 (1998) 23-30
22. Balanescu S., Corlan A.D., Dorobantu M., and Gherasim L. Prognostic value of heart rate variability after acute myocardial infarction. Med Sci Monit 10 (2004) CR307-CR315
23. Miwa K., Igawa A., Miyagi Y., Nakagawa K., and Inoue H. Alterations of autonomic nervous activity preceding nocturnal variant angina: sympathetic augmentation with parasympathetic impairment. Am Heart J 135 (1998) 762-771
24. Kupper N.H., Willemsen G., van den Berg M., et al. Heritability of ambulatory heart rate variability. Circulation 110 (2004) 2792-2796
25. Dantzer R., Konsman J.P., Bluthe R.M., and Kelley K.W. Neural and humoral pathways of communication from the immune system to the brain: parallel or convergent?. Auton Neurosci 85 (2000) 60-65
26. Davidson J., Abul H.T., Milton A.S., and Rotondo D. Cytokines and cytokine inducers stimulate prostaglandin E2 entry into the brain. Pflugers Arch 442 (2001) 526-533
27. Ek M., Kurosawa M., Lundeberg T., and Ericsson A. Activation of vagal afferents after intravenous injection of interleukin-1beta: role of endogenous prostaglandins. J Neurosci 18 (1998) 9471-9479
28. Fleshner M., Goehler L.E., Hermann J., Relton J.K., Maier S.F., and Watkins L.R. Interleukin-1 beta induced corticosterone elevation and hypothalamic NE depletion is vagally mediated. Brain Res Bull 37 (1995) 605-610
29. Goehler L.E., Gaykema R.P., Hammack S.E., Maier S.F., and Watkins L.R. Interleukin-1 induces c-Fos immunoreactivity in primary afferent neurons of the vagus nerve. Brain Res 804 (1998) 306-310
30. Maier S.F., Goehler L.E., Fleshner M., and Watkins L.R. The role of the vagus nerve in cytokine-to-brain communication. Ann NY Acad Sci 840 (1998) 289-300
31. Kwaijtaal M., van Diest R., x00e r.F.W., et al. Inflammatory markers predict late cardiac events in patients who are exhausted after percutaneous coronary intervention. Atherosclerosis 182 (2005) 341
32. Waehre T., Yndestad A., Smith C., et al. Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors. Circulation 109 (2004) 1966-1972
33. Van Dam A.-M., Bol J.G.J.M., Gaykema R.P.A., et al. Vagotomy does not inhibit high dose lipopolysaccharide-induced interleukin-1[beta] immunoreactivity in rat brain and pituitary gland. Neurosci Lett 285 (2000) 169
34. Hansen M.K., Daniels S., Goehler L.E., Gaykema R.P., Maier S.F., and Watkins L.R. Subdiaphragmatic vagotomy does not block intraperitoneal lipopolysaccharide-induced fever. Auton Neurosci 85 (2000) 83-87
35. Funayama H., Ishikawa S.E., Kubo N., et al. Increases in interleukin-6 and matrix metalloproteinase-9 in the infarct-related coronary artery of acute myocardial infarction. Circ J 68 (2004) 451-454
36. Markos F., Snow H.M., Kidd C., and Conlon K. Nitric oxide facilitates vagal control of heart rate via actions in the cardiac parasympathetic ganglia of the anaesthetised dog. Exp Physiol 87 (2002) 49-52
37. Dantzer R. Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. Eur J Pharmacol 500 (2004) 399
38. Konsman J.P., Vigues S., Mackerlova L., Bristow A.F., and Blomqvist A. Rat brain vascular distribution of interleukin-1 type-1 receptor immunoreactivity: relationship to patterns of inducible cyclooxygenase expression by peripheral inflammatory stimuli. J Compar Neurol 472 (2004) 113-129
39. Xu Y., Day T.A., and Buller K.M. The central amygdala modulates hypothalamic-pituitary-adrenal axis responses to systemic interleukin-1[beta] administration. Neuroscience 94 (1999) 175
40. Weiss J.M., Quan N., and Sundar S.K. Widespread activation and consequences of interleukin-1 in the brain. Ann NY Acad Sci 741 (1994) 338-357
41. Berntson G.G., Cacioppo J.T., and Quigley K.S. Cardiac psychophysiology and autonomic space in humans: empirical perspectives and conceptual implications. Psychol Bull 114 (1993) 296-322
42. Longhurst J.C., Tjen-A-Looi S.C., and Fu L.-W. Cardiac sympathetic afferent activation provoked by myocardial ischemia and reperfusion: mechanisms and reflexes. Ann NY Acad Sci 940 (2001) 74-95
43. Tjen-A-Looi S., Bonham A., and Longhurst J. Interactions between sympathetic and vagal cardiac afferents in nucleus tractus solitarii. Am J Physiol Heart Circ Physiol 272 (1997) H2843-H2851
44. Berntson G.G., Sarter M., and Cacioppo J.T. Autonomic nervous system. In: Nadel L. (Ed). Encyclopedia of cognitive science (2003), Nature Publishing Group, London 301-308
45. Matthews S.C., Paulus M.P., Simmons A.N., Nelesen R.A., and Dimsdale J.E. Functional subdivisions within anterior cingulate cortex and their relationship to autonomic nervous system function. NeuroImage 22 (2004) 1151
46. Plotsky P.M., Otto S., and Sutton S. Neurotransmitter modulation of corticotropin releasing factor secretion into the hypophysial-portal circulation. Life Sci 41 (1987) 1311-1317
47. Wiersma A., Bohus B., and Koolhaas J.M. Corticotropin-releasing hormone microinfusion in the central amygdala diminishes a cardiac parasympathetic outflow under stress-free conditions. Brain Res 625 (1993) 219-227
48. Wiersma A., Knollema S., Konsman J.P., Bohus B., and Koolhaas J.M. Corticotropin-releasing hormone modulation of a conditioned stress response in the central amygdala of Roman high (RHA/Verh)-avoidance and low (RLA/Verh)-avoidance rats. Behav Genet 27 (1997) 547-555
49. Akiyama T., and Yamazaki T. Adrenergic inhibition of endogenous acetylcholine release on post-ganglionic cardiac vagal nerve terminals. Cardiovasc Res 46 (2000) 531
50. Schwertfeger E., Klein T., Vonend O., Oberhauser V., Stegbauer J., and Rump L.C. Neuropeptide Y inhibits acetylcholine release in human heart atrium by activation of Y2-receptors. Naunyn Schmiedebergs Arch Pharmacol 369 (2004) 455-461
51. Bedoui S., Kawamura N., Straub R.H., Pabst R., Yamamura T., and von Horsten S. Relevance of neuropeptide Y for the neuroimmune crosstalk. J Neuroimmunol 134 (2003) 1-11
52. Straub R.H., Schaller T., Miller L.E., et al. Neuropeptide Y cotransmission with norepinephrine in the sympathetic nerve-macrophage interplay. J Neurochem 75 (2000) 2464
53. Smith-White M.A., Iismaa T.P., and Potter E.K. Galanin and neuropeptide Y reduce cholinergic transmission in the heart of the anaesthetised mouse. Br. J. Pharmacol 140 (2003) 170-178
54. Anand A., Li Y., Wang Y., et al. Activity and connectivity of brain mood regulating circuit in depression: a functional magnetic resonance study. Biol Psychiatry 57 (2005) 1079
55. Carney R.M., Blumenthal J.A., Stein P.K., et al. Depression, heart rate variability, and acute myocardial infarction. Circulation 104 (2001) 2024-2028
56. Barth J., Schumacher M., and Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med 66 (2004) 802-813
57. Carney R.M., Blumenthal J.A., Stein P.K., et al. Depression, heart rate variability, and acute myocardial infarction. Circulation 104 (2001) 2024-2028
58. Carney R.M., Blumenthal J.A., Freedland K.E., et al. Low heart rate variability and the effect of depression on post-myocardial infarction mortality. Arch Intern Med 165 (2005) 1486-1491
59. Lorberbaum J.P., Kose S., Johnson M.R., et al. Neural correlates of speech anticipatory anxiety in generalized social phobia. Neuroreport 15 (2004) 2701-2705
60. Davidson R.J., Marshall J.R., Tomarken A.J., and Henriques J.B. While a phobic waits: regional brain electrical and autonomic activity in social phobics during anticipation of public speaking. Biol Psychiatry 47 (2000) 85
61. Friedman B.H., and Thayer J.F. Anxiety and autonomic flexibility: a cardiovascular approach. Biol Psychology 47 (1998) 243
62. Pfiffner D., and Hoffmann A. Psychosocial predictors of death for low-risk patients after a first myocardial infarction: a 7-year follow-up study. J Cardiopulm Rehabil 24 (2004) 87-93
63. Strik J.J.M.H., Denollet J., Lousberg R., and Honig A. Comparing symptoms of depression and anxiety as predictors of cardiac events and increased health care consumption after myocardial infarction. J Am Coll Cardiol 42 (2003) 1801
64. Reichenberg A., Yirmiya R., Schuld A., et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 58 (2001) 445-452
65. Denollet J., Sys S.U., Stroobant N., Rombouts H., Gillebert T.C., and Brutsaert D.L. Personality as independent predictor of long-term mortality in patients with coronary heart disease. Lancet 347 (1996) 417-421
66. Denollet J., Vaes J., and Brutsaert D.L. Inadequate response to treatment in coronary heart disease: adverse effects of type D personality and younger age on 5-year prognosis and quality of life. Circulation 102 (2000) 630-635
67. Pedersen S.S., Lemos P.A., van Vooren P.R., et al. Type D personality predicts death or myocardial infarction after bare metal stent or sirolimus-eluting stent implantation: a rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital (Research) registry substudy. J Am Coll Cardiol 44 (2004) 997-1001
68. van Dixhoorn J., and White A. Relaxation therapy for rehabilitation and prevention in ischaemic heart disease: a systematic review and meta-analysis. Eur J Cardiovasc Prev Rehabil 12 (2005) 193-202
69. Carlson L.E., Speca M., Patel K.D., and Goodey E. Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress, and immune parameters in breast and prostate cancer outpatients. Psychosom Med 65 (2003) 571-581
70. Nolan R.P., Kamath M.V., Floras J.S., et al. Heart rate variability biofeedback as a behavioral neurocardiac intervention to enhance vagal heart rate control. Am Heart J 149 (2005) 1137
71. Zamotrinsky A.V., Kondratiev B., and de Jong J.W. Vagal neurostimulation in patients with coronary artery disease. Auton Neurosci 88 (2001) 109-116
72. Bernik T.R., Friedman S.G., Ochani M., et al. Cholinergic antiinflammatory pathway inhibition of tumor necrosis factor during ischemia reperfusion. J Vasc Surg 36 (2002) 1231
73. Valgimigli M., Ceconi C., Malagutti P., et al. Tumor necrosis factor-{alpha} receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the cytokine-activation and long-term prognosis in myocardial infarction (C-ALPHA) study. Circulation 111 (2005) 863-870
74. Koukkunen H., Penttila K., Kemppainen A., et al. C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-alpha in the prognostic classification of unstable angina pectoris. Ann Med 33 (2001) 37-47
75. Li M., Zheng C., Sato T., Kawada T., Sugimachi M., and Sunagawa K. Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation 109 (2004) 120-124
76. Springer J., Okonko D.O., Anker S.D., et al. Vagal nerve stimulation in chronic heart failure: an antiinflammatory intervention? * response. Circulation 110 (2004) e34
77. Torre-Amione G. Immune activation in chronic heart failure. Am J Cardiol 95 (2005) 3
78. Corcoran C., Connor T.J., O'Keane V., and Garland M.R. The effects of vagus nerve stimulation on pro- and anti-inflammatory cytokines in humans: a preliminary report. Neuroimmunomodulation 12 (2005) 307
79. La Rovere M.T., Mortara A., Pantaleo P., Maestri R., Cobelli F., and Tavazzi L. Scopolamine improves autonomic balance in advanced congestive heart failure. Circulation 90 (1994) 838-843
80. Halliwill J.R., Billman G.E., and Eckberg D.L. Effect of a 'vagomimetic' atropine dose on canine cardiac vagal tone and susceptibility to sudden cardiac death. Clin Auton Res 8 (1998) 155-164
81. Wang L., Wang L., Zhang Y., Zhang B., and Chen M. Low dose transdermal scopolamine increases cardiac vagal tone in patients after acute myocardial infarction. Chin Med J (Engl) 115 (2002) 770-772
82. Armour J.A. Cardiac neuronal hierarchy in health and disease. Am J Physiol Regul Integr Comp Physiol 287 (2004) R262-R271
83. Samuels M.A. Neurally induced cardiac damage. definition of the problem. Neurol Clin 11 (1993) 273-292
84. Ter Horst G.J. Central autonomic control of the heart, angina, and pathogenic mechanisms of post-myocardial infarction depression. Eur J Morphol 37 (1999) 257-266
85. Aronson D., Mittleman M.A., and Burger A.J. Interleukin-6 levels are inversely correlated with heart rate variability in patients with decompensated heart failure. J Cardiovasc Electrophysiol 12 (2001) 294-300
86. Janszky I., Ericson M., Lekander M., et al. Inflammatory markers and heart rate variability in women with coronary heart disease. J Intern Med 256 (2004) 421-428
87. Singh R.B., Kartik C., Otsuka K., Pella D., and Pella J. Brain-heart connection and the risk of heart attack. Biomed Pharmacother 56 Suppl. 2 (2002) 257s-265s
88. McLean K.J., Jarrott B., and Lawrence A.J. Prepro-neuropeptide Y mRNA and NPY binding sites in human inferior vagal ganglia. Neuroreport 8 (1997) 2317-2320